Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Healthcare Biotechnology
Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Sirona Biochem Corp > No quarterly update?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(11)
•••
Comment by gr0und1ngon Jul 18, 2024 3:42am
167 Views
Post# 36137834

RE:RE:RE:RE:No quarterly update?

RE:RE:RE:RE:No quarterly update?
Something new is coming,
with or without TFC-1067!
--------------------------------

APRIL 8, 2024 / Sirona Biochem / Allergan is actively progressing the integration of TFC-1067 into its product line
 
JANUARY 23, 2024 / Sirona Biochem / Allergan continues to work on the integration of TFC-1067 into its pipeline

AUGUST 30, 2023 / Allergan Sales, LLC / Patent - Topical Hyperpigmentation Compositions and Method of Use
 
MARCH 2023 / Elizabeth T Makino - Allergan / Evaluation of Efficacy and Tolerability (LYT3 vs 4% Hydroquinone)
 
Mar 2023 / Elizabeth T Makino - Allergan / Evaluation of cosmetic changes (LYT3 and Spot Tx)
 
MARCH 2023 / Elizabeth T Makino - Allergan / Evaluation of efficacy and tolerability (Spot Tx)
 
JANUARY 17, 2023 / AbbVie News Center / SkinMedica® Launches Even &amp; Correct 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities